Cost-effectiveness analysis of transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma treatment options—Experience of the efficiency frontier approach.
Kurte MS, Siefen, A-C, Jakobs F, von Tresckow B, Reinhardt HC, & Kron, F
29. August 2023